ORPHA:1824
Lowry-Wood syndrome
Also known as: Epiphyseal dysplasia-microcephaly-nystagmus syndrome
Publications
316
71.9th percentile
Trials
1
Interventional, condition-specific
Researchers
500
Distinct authors in sample
Gene link
RNU4ATAC
Limited
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder characterized by the association of epiphyseal , short stature, microcephaly and, in the first reported cases, nystagmus. So far, less than 10 cases have been described in the literature. Variable degrees of intellectual deficit have also been reported. Other occasional features include retinitis pigmentosa and coxa vara. Transmission appears to be .
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009191
- MeSH:C537038
- OMIM:226960
- UMLS:C0796021
Additional Mondo synonyms (4)
LWS · Lowry Wood syndrome · epiphyseal dysplasia, multiple, with microcephaly and retinal dystrophy · epiphyseal dysplasia-microcephaly-nystagmus syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Limited — RNU4ATAC
- LiteraturePresent
316 matched papers (249 in last 10 years) Source
- Phenotype characterisedPresent
46 HPO annotations (e.g. Platyspondyly; Intellectual disability; Joint stiffness) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for RNU4ATAC.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
46
Associated phenotypes · MONDO:0009191
- Platyspondyly
- Intellectual disability
- Joint stiffness
- Patellar dislocation
- Elbow dislocation
Showing 5 of 46 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
316
316 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
316 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
249 in the last 10 years · medium confidence · 71.9th percentile (publications denominator)
Phrase hits: 62 · MeSH hits: 0
Who's working on it?
500
Distinct author names in 62 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Kanadia RN9 papers · 2022
Physiology and Neurobiology Department, University of Connecticut, Storrs, CT, 06269, USA. Rahul.kanadia@uconn.edu.
Papers in Europe PMC - 02Olthof AM6 papers · 2022
Physiology and Neurobiology Department, University of Connecticut, Storrs, CT, 06269, USA.
Papers in Europe PMC - 03Bernstein JA4 papers · 2026
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Papers in Europe PMC - 04Campeau PM4 papers · 2021
Divisions of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada. p.campeau@umontreal.ca.
Papers in Europe PMC - 05Frilander MJ4 papers · 2026
Institute of Biotechnology, P.O. Box 56, Viikinkaari 5, University of Helsinki, FI-00014 Helsinki, Finland.
Papers in Europe PMC - 06Magnani C4 papers · 2021
Department of Pediatrics, University Hospital, Parma, Italy. cmagnani@unipr.it
Papers in Europe PMC - 07Wheeler MT4 papers · 2026
Department of Medicine, Stanford University, Stanford, CA, USA.
Papers in Europe PMC - 08White AK4 papers · 2022
Physiology and Neurobiology Department, University of Connecticut, Storrs, CT 06269, USA.
Papers in Europe PMC - 09Aquino GS3 papers · 2021
Physiology and Neurobiology Department, University of Connecticut, Storrs, CT 06269, USA.
Papers in Europe PMC - 10Baumgartner M3 papers · 2021
Department of Genetics, Yale School of Medicine, New Haven, CT 06510, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
medium confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06111950·RECRUITING·Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes
Not reviewed·Conditions: Taybi Linder Syndrome · Microcephalic Osteodysplastic Primordial Dwarfism Types I and III · Roifman Syndrome · Lowry Wood Syndrome·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04569149·RECRUITING·Primordial Dwarfism Registry
Not reviewed·Conditions: MOPDII · Meier-Gorlin Syndrome · Saul-Wilson Syndrome · Microcephalic Primordial Dwarfism·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Lowry-Wood syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Lowry-Wood syndrome" OR "Epiphyseal dysplasia-microcephaly-nystagmus syndrome" OR "Lowry Wood syndrome" OR "epiphyseal dysplasia, multiple, with microcephaly and retinal dystrophy") OR ("RNU4ATAC" OR "RNU4ATAC syndrome" OR "RNU4ATAC-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lowry-Wood syndrome" OR "Epiphyseal dysplasia-microcephaly-nystagmus syndrome" OR "Lowry Wood syndrome" OR "epiphyseal dysplasia, multiple, with microcephaly and retinal dystrophy"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: LWS
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T18:14:51.102Z
